Report cover image

Global CAR T-Cell Therapy Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20361020

Description

Summary

According to APO Research, The global CAR T-Cell Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for CAR T-Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of CAR T-Cell Therapy include J & J, Novartis, Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), JW Therapeutics, Gilead Sciences, FOSUNKite, Celyad(Pipeline) and Cellectis(Pipeline), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CAR T-Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of CAR T-Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for CAR T-Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR T-Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global CAR T-Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for CAR T-Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

CAR T-Cell Therapy Segment by Company

J & J
Novartis
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
JW Therapeutics
Gilead Sciences
FOSUNKite
Celyad(Pipeline)
Cellectis(Pipeline)
CARsgen Therapeutics (Pipeline)
Bristol-Myers Squibb
Bluebird Bio(Pipeline)
Autolus Therapeutics(Pipeline)
Allogene Therapeutics(Pipeline)
CAR T-Cell Therapy Segment by Type

CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Segment by Application

Lymphoma
Multiple Myeloma
CAR T-Cell Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CAR T-Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CAR T-Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 CAR T-Cell Therapy Market by Type
1.2.1 Global CAR T-Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 CD19 - Targeted
1.2.3 BCMA - Targeted
1.3 CAR T-Cell Therapy Market by Application
1.3.1 Global CAR T-Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CAR T-Cell Therapy Market Dynamics
2.1 CAR T-Cell Therapy Industry Trends
2.2 CAR T-Cell Therapy Industry Drivers
2.3 CAR T-Cell Therapy Industry Opportunities and Challenges
2.4 CAR T-Cell Therapy Industry Restraints
3 Global Growth Perspective
3.1 Global CAR T-Cell Therapy Market Perspective (2020-2031)
3.2 Global CAR T-Cell Therapy Growth Trends by Region
3.2.1 Global CAR T-Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global CAR T-Cell Therapy Market Size by Region (2020-2025)
3.2.3 Global CAR T-Cell Therapy Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global CAR T-Cell Therapy Revenue by Players
4.1.1 Global CAR T-Cell Therapy Revenue by Players (2020-2025)
4.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2020-2025)
4.1.3 Global CAR T-Cell Therapy Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global CAR T-Cell Therapy Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global CAR T-Cell Therapy Key Players Headquarters & Area Served
4.4 Global CAR T-Cell Therapy Players, Product Type & Application
4.5 Global CAR T-Cell Therapy Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global CAR T-Cell Therapy Market CR5 and HHI
4.6.3 2024 CAR T-Cell Therapy Tier 1, Tier 2, and Tier 3
5 CAR T-Cell Therapy Market Size by Type
5.1 Global CAR T-Cell Therapy Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global CAR T-Cell Therapy Revenue by Type (2020-2031)
5.3 Global CAR T-Cell Therapy Revenue Market Share by Type (2020-2031)
6 CAR T-Cell Therapy Market Size by Application
6.1 Global CAR T-Cell Therapy Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global CAR T-Cell Therapy Revenue by Application (2020-2031)
6.3 Global CAR T-Cell Therapy Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 J & J
7.1.1 J & J Comapny Information
7.1.2 J & J Business Overview
7.1.3 J & J CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.1.4 J & J CAR T-Cell Therapy Product Portfolio
7.1.5 J & J Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.2.4 Novartis CAR T-Cell Therapy Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Sorrento Therapeutics(Pipeline)
7.3.1 Sorrento Therapeutics(Pipeline) Comapny Information
7.3.2 Sorrento Therapeutics(Pipeline) Business Overview
7.3.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.3.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
7.3.5 Sorrento Therapeutics(Pipeline) Recent Developments
7.4 Mustang Bio(Pipeline)
7.4.1 Mustang Bio(Pipeline) Comapny Information
7.4.2 Mustang Bio(Pipeline) Business Overview
7.4.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.4.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
7.4.5 Mustang Bio(Pipeline) Recent Developments
7.5 JW Therapeutics
7.5.1 JW Therapeutics Comapny Information
7.5.2 JW Therapeutics Business Overview
7.5.3 JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.5.4 JW Therapeutics CAR T-Cell Therapy Product Portfolio
7.5.5 JW Therapeutics Recent Developments
7.6 Gilead Sciences
7.6.1 Gilead Sciences Comapny Information
7.6.2 Gilead Sciences Business Overview
7.6.3 Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.6.4 Gilead Sciences CAR T-Cell Therapy Product Portfolio
7.6.5 Gilead Sciences Recent Developments
7.7 FOSUNKite
7.7.1 FOSUNKite Comapny Information
7.7.2 FOSUNKite Business Overview
7.7.3 FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.7.4 FOSUNKite CAR T-Cell Therapy Product Portfolio
7.7.5 FOSUNKite Recent Developments
7.8 Celyad(Pipeline)
7.8.1 Celyad(Pipeline) Comapny Information
7.8.2 Celyad(Pipeline) Business Overview
7.8.3 Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.8.4 Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio
7.8.5 Celyad(Pipeline) Recent Developments
7.9 Cellectis(Pipeline)
7.9.1 Cellectis(Pipeline) Comapny Information
7.9.2 Cellectis(Pipeline) Business Overview
7.9.3 Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.9.4 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
7.9.5 Cellectis(Pipeline) Recent Developments
7.10 CARsgen Therapeutics (Pipeline)
7.10.1 CARsgen Therapeutics (Pipeline) Comapny Information
7.10.2 CARsgen Therapeutics (Pipeline) Business Overview
7.10.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.10.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
7.10.5 CARsgen Therapeutics (Pipeline) Recent Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Comapny Information
7.11.2 Bristol-Myers Squibb Business Overview
7.11.3 Bristol-Myers Squibb CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.11.4 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
7.11.5 Bristol-Myers Squibb Recent Developments
7.12 Bluebird Bio(Pipeline)
7.12.1 Bluebird Bio(Pipeline) Comapny Information
7.12.2 Bluebird Bio(Pipeline) Business Overview
7.12.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.12.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
7.12.5 Bluebird Bio(Pipeline) Recent Developments
7.13 Autolus Therapeutics(Pipeline)
7.13.1 Autolus Therapeutics(Pipeline) Comapny Information
7.13.2 Autolus Therapeutics(Pipeline) Business Overview
7.13.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.13.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
7.13.5 Autolus Therapeutics(Pipeline) Recent Developments
7.14 Allogene Therapeutics(Pipeline)
7.14.1 Allogene Therapeutics(Pipeline) Comapny Information
7.14.2 Allogene Therapeutics(Pipeline) Business Overview
7.14.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2020-2025)
7.14.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
7.14.5 Allogene Therapeutics(Pipeline) Recent Developments
8 North America
8.1 North America CAR T-Cell Therapy Revenue (2020-2031)
8.2 North America CAR T-Cell Therapy Revenue by Type (2020-2031)
8.2.1 North America CAR T-Cell Therapy Revenue by Type (2020-2025)
8.2.2 North America CAR T-Cell Therapy Revenue by Type (2026-2031)
8.3 North America CAR T-Cell Therapy Revenue Share by Type (2020-2031)
8.4 North America CAR T-Cell Therapy Revenue by Application (2020-2031)
8.4.1 North America CAR T-Cell Therapy Revenue by Application (2020-2025)
8.4.2 North America CAR T-Cell Therapy Revenue by Application (2026-2031)
8.5 North America CAR T-Cell Therapy Revenue Share by Application (2020-2031)
8.6 North America CAR T-Cell Therapy Revenue by Country
8.6.1 North America CAR T-Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America CAR T-Cell Therapy Revenue by Country (2020-2025)
8.6.3 North America CAR T-Cell Therapy Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe CAR T-Cell Therapy Revenue (2020-2031)
9.2 Europe CAR T-Cell Therapy Revenue by Type (2020-2031)
9.2.1 Europe CAR T-Cell Therapy Revenue by Type (2020-2025)
9.2.2 Europe CAR T-Cell Therapy Revenue by Type (2026-2031)
9.3 Europe CAR T-Cell Therapy Revenue Share by Type (2020-2031)
9.4 Europe CAR T-Cell Therapy Revenue by Application (2020-2031)
9.4.1 Europe CAR T-Cell Therapy Revenue by Application (2020-2025)
9.4.2 Europe CAR T-Cell Therapy Revenue by Application (2026-2031)
9.5 Europe CAR T-Cell Therapy Revenue Share by Application (2020-2031)
9.6 Europe CAR T-Cell Therapy Revenue by Country
9.6.1 Europe CAR T-Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe CAR T-Cell Therapy Revenue by Country (2020-2025)
9.6.3 Europe CAR T-Cell Therapy Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China CAR T-Cell Therapy Revenue (2020-2031)
10.2 China CAR T-Cell Therapy Revenue by Type (2020-2031)
10.2.1 China CAR T-Cell Therapy Revenue by Type (2020-2025)
10.2.2 China CAR T-Cell Therapy Revenue by Type (2026-2031)
10.3 China CAR T-Cell Therapy Revenue Share by Type (2020-2031)
10.4 China CAR T-Cell Therapy Revenue by Application (2020-2031)
10.4.1 China CAR T-Cell Therapy Revenue by Application (2020-2025)
10.4.2 China CAR T-Cell Therapy Revenue by Application (2026-2031)
10.5 China CAR T-Cell Therapy Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia CAR T-Cell Therapy Revenue (2020-2031)
11.2 Asia CAR T-Cell Therapy Revenue by Type (2020-2031)
11.2.1 Asia CAR T-Cell Therapy Revenue by Type (2020-2025)
11.2.2 Asia CAR T-Cell Therapy Revenue by Type (2026-2031)
11.3 Asia CAR T-Cell Therapy Revenue Share by Type (2020-2031)
11.4 Asia CAR T-Cell Therapy Revenue by Application (2020-2031)
11.4.1 Asia CAR T-Cell Therapy Revenue by Application (2020-2025)
11.4.2 Asia CAR T-Cell Therapy Revenue by Application (2026-2031)
11.5 Asia CAR T-Cell Therapy Revenue Share by Application (2020-2031)
11.6 Asia CAR T-Cell Therapy Revenue by Country
11.6.1 Asia CAR T-Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia CAR T-Cell Therapy Revenue by Country (2020-2025)
11.6.3 Asia CAR T-Cell Therapy Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA CAR T-Cell Therapy Revenue (2020-2031)
12.2 SAMEA CAR T-Cell Therapy Revenue by Type (2020-2031)
12.2.1 SAMEA CAR T-Cell Therapy Revenue by Type (2020-2025)
12.2.2 SAMEA CAR T-Cell Therapy Revenue by Type (2026-2031)
12.3 SAMEA CAR T-Cell Therapy Revenue Share by Type (2020-2031)
12.4 SAMEA CAR T-Cell Therapy Revenue by Application (2020-2031)
12.4.1 SAMEA CAR T-Cell Therapy Revenue by Application (2020-2025)
12.4.2 SAMEA CAR T-Cell Therapy Revenue by Application (2026-2031)
12.5 SAMEA CAR T-Cell Therapy Revenue Share by Application (2020-2031)
12.6 SAMEA CAR T-Cell Therapy Revenue by Country
12.6.1 SAMEA CAR T-Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA CAR T-Cell Therapy Revenue by Country (2020-2025)
12.6.3 SAMEA CAR T-Cell Therapy Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.